May 28th, 2024 Ubiquigent collaborates with University of Glasgow on structural basis for the mechanism of action of clinical USP1 inhibitor
March 26th, 2024 Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
October 3rd, 2023 Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies